10.6084/m9.figshare.3980160.v1 Akane Yamamichi Akane Yamamichi Toshihiro Kasama Toshihiro Kasama Fumiharu Ohka Fumiharu Ohka Hiromichi Suzuki Hiromichi Suzuki Akira Kato Akira Kato Kazuya Motomura Kazuya Motomura Masaki Hirano Masaki Hirano Melissa Ranjit Melissa Ranjit Lushun Chalise Lushun Chalise Michihiro Kurimoto Michihiro Kurimoto Goro Kondo Goro Kondo Kosuke Aoki Kosuke Aoki Noritada Kaji Noritada Kaji Manabu Tokeshi Manabu Tokeshi Toshio Matsubara Toshio Matsubara Takeshi Senga Takeshi Senga Mika K. Kaneko Mika K. Kaneko Hidenori Suzuki Hidenori Suzuki Masahito Hara Masahito Hara Toshihiko Wakabayashi Toshihiko Wakabayashi Yoshinobu Baba Yoshinobu Baba Yukinari Kato Yukinari Kato Atsushi Natsume Atsushi Natsume An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas Taylor & Francis Group 2016 Glioma isocitrate dehydrogenase 1 mutation immuno-wall microdevice rapid diagnosis precision medicine 30 Bio-inspired and biomedical materials 404 Materials informatics / Genomics 2016-10-04 10:51:07 Dataset https://tandf.figshare.com/articles/dataset/An_immuno-wall_microdevice_exhibits_rapid_and_sensitive_detection_of_IDH1-R132H_mutation_specific_to_grade_II_and_III_gliomas/3980160 <p>World Health Organization grade II and III gliomas most frequently occur in the central nervous system (CNS) in adults. Gliomas are not circumscribed; tumor edges are irregular and consist of tumor cells, normal brain tissue, and hyperplastic reactive glial cells. Therefore, the tumors are not fully resectable, resulting in recurrence, malignant progression, and eventual death. Approximately 69–80% of grade II and III gliomas harbor mutations in the isocitrate dehydrogenase 1 gene (<i>IDH1</i>), of which 83–90% are found to be the <i>IDH1-R132H</i> mutation. Detection of the <i>IDH1-R132H</i> mutation should help in the differential diagnosis of grade II and III gliomas from other types of CNS tumors and help determine the boundary between the tumor and normal brain tissue. In this study, we established a highly sensitive antibody-based device, referred to as the immuno-wall, to detect the <i>IDH1-R132H</i> mutation in gliomas. The immuno-wall causes an immunoreaction in microchannels fabricated using a photo-polymerizing polymer. This microdevice enables the analysis of the <i>IDH1</i> status with a small sample within 15 min with substantially high sensitivity. Our results suggested that 10% content of the <i>IDH1-R132H</i> mutation in a sample of 0.33 μl volume, with 500 ng protein, or from 500 cells is theoretically sufficient for the analysis. The immuno-wall device will enable the rapid and highly sensitive detection of the <i>IDH1-R132H</i> mutation in routine clinical practice.</p>